Abstract
No public abstract is available from the verified source records.
Francisco Epelde Gonzalo, María Pilar Martínez López
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Low-density lipoproteins cause atherosclerotic cardiovascular disease
10.1093/eurheartj/ehx144 · 2017
Cholesterol Treatment trialists' (CTT) collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
10.1016/s0140-6736(12)60367-5 · 2012
Pitavastatin to prevent cardiovascular disease in HIV infection
10.1056/nejmoa2304146 · 2023
Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients
10.1001/jama.2023.9696 · 2023
STAREE Investigators. Atorvastatin, cardiovascular events, and disability-free survival in older adults
10.1056/nejmoa2607314 · 2026
VESALIUS-CV investigators. Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes
10.1001/jama.2026.3277 · 2026
2025 Focused update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
10.1093/eurheartj/ehaf190 · 2025
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
10.1016/j.jacc.2025.11.016 · 2026
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
10.1016/s0140-6736(18)31942-1 · 2019
Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis
10.1001/jamainternmed.2020.6084 · 2021
No additional external references are available.